Revisional bariatric surgery after adjustable gastric band: a multicenter Polish Revision Obesity Surgery Study (PROSS).

Autor: Dowgiałło-Gornowicz, Natalia, Janik, Michał, Lech, Paweł, Kowalski, Grzegorz, Major, Piotr, PROSS –Collaborative Study Group, Pędziwiatr, Michał, Rymarowicz, Justyna, Zarzycki, Piotr, Stefura, Tomasz, Ciszek, Karol, Małczak, Piotr, Myśliwiec, Piotr, Hady, Hady Razak, Głuszyńska, Paulina, Proczko-Stepaniak, Monika, Szymański, Michał, Walędziak, Maciej, Kwiatkowski, Andrzej, Materlak, Magdalena
Předmět:
Zdroj: BMC Surgery; 4/20/2023, Vol. 23 Issue 1, p1-6, 6p
Abstrakt: Background: Adjustable gastric band (AGB) hadbeen the preferred treatment for morbid obesity because it is minimally invasive and reversible. But now it seems to be slowly becoming a historic procedure due to the disappointing effects. The aim of the study was to systematize and present the available data on revisional bariatric surgery (RBS) after AGB among Polish patients. Methods: It is a multicenter, retrospective analysis of patients undergoing laparoscopic RBS after AGB in 12 Polish bariatric centers. The database included patient demographics, comorbidities and surgical outcomes. Results: The group consisted of 234 patients who underwent AGB, which accounted for 29% of revisional cases recorded in the Polish Revisional Obesity Surgery Study (PROSS). 195 were women (83%), and 39 were men (17%). One hundred seventy-five patients after AGB experienced a weight regain (74.5%), 36 patients a gastric band slippage (15.0%), 14 patients had gastric band intolerance (6.0%). Types of RBS included 116 sleeve gastrectomies (SG) (49.4%), 86 Roux-en Y gastric by-passes (RYGB) (36.6%), 20 one anastomosis gastric by-passes (OAGB) (8,5%). The highest weight loss expressed as %EBMIL was observed after OAGB (63.5 ± 32.4%). Conclusions: The main indication for RBS after AGB was weight regain. SG was the most frequently chosen type of RBS after AGB. RBS after AGB leads to weight loss and improvement in type 2 diabetes and hypertension with an acceptable low risk of complications. Trial registration: NCT05108532. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index